Results 31 to 40 of about 72,405 (280)

Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease

open access: yesPharmaceuticals, 2013
Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn’s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns.
George Alex   +3 more
doaj   +1 more source

Infliximab treatment in pathology-confirmed neurosarcoidosis [PDF]

open access: yes, 2020
OBJECTIVE: To assess the efficacy and risks of treatment with infliximab (anti-tumor necrosis factor alpha) in pathology-confirmed neurosarcoidosis. METHODS: In a retrospective study in 2 tertiary referral centers in the Netherlands, we analyzed clinical
Siepman, T.A.M. (Theodora)   +20 more
core   +1 more source

Discontinuation of Infliximab Therapy in Patients with Crohn’s Disease

open access: yes, 2022
BACKGROUNDWhether infliximab therapy can be successfully discontinued after patients with Crohn’s disease have attained sustained, clinical, biochemical, and endoscopic remission is unknown.METHODSWe conducted a multicenter, randomized, double-blind ...
Østergaard, Thomsen Ole   +63 more
core   +2 more sources

Establishment of a Multi‐Stage In Vitro Screening Platform to Identify Candidate Compounds for Intestinal Mucosal Damage in Inflammatory Bowel Disease

open access: yesAdvanced Healthcare Materials, EarlyView.
A multi‐stage screening platform integrating human intestinal organoids with an intestinal microphysiological system enables evaluation of both inflammatory responses and mucosal architecture in inflammatory bowel disease. The platform distinguishes compounds that suppress inflammation from those that also preserve mucosal architecture, providing a ...
Fuki Yokoi   +8 more
wiley   +1 more source

Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. [PDF]

open access: yesPLoS ONE, 2017
Infliximab is an effective treatment for inflammatory bowel disease (IBD). Studies differ regarding the influence of body mass index (BMI) on the response to infliximab, with the majority of studies indicating that increased BMI may be associated with a ...
Franco Scaldaferri   +15 more
doaj   +1 more source

Copper‐Driven Epithelial Barrier Disruption: A Novel Mechanism of COPD Acute Exacerbations Mediated by the TNF‐α/ATP7A Axis

open access: yesAdvanced Science, EarlyView.
This study reveals a copper‐driven mechanism of COPD acute exacerbations mediated by the TNF‐α/ATP7A axis. TNF‐α suppresses the copper transporter ATP7A via competitive NF‐κB/CREB1/CBP signaling, resulting in intracellular copper accumulation, mitochondrial oxidative stress, and epithelial barrier disruption.
Xinru Xiao   +7 more
wiley   +1 more source

Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System

open access: yesChildren
Background/Objectives: Infliximab biosimilars entered the United States (US) market in November 2016. Uptake of infliximab biosimilars has been slow in adult studies.
Ross M. Maltz   +2 more
doaj   +1 more source

Advancing Biotherapeutic Treatment of Ulcerative Colitis Using Lipid Mesophases: Formulation Design and Preclinical Validation

open access: yesAdvanced Science, EarlyView.
Lipid mesophases provide a versatile platform for colon‐targeted delivery of biotherapeutics, protecting them from degradation while enhancing mucoadhesion and enabling localized, controlled release to the inflamed mucosa after oral or rectal administration. In a DSS‐induced colitis model, this strategy reduced disease activity, inflammatory biomarkers,
Rafaela Gazzi   +13 more
wiley   +1 more source

Early Serum Infliximab Levels in Pediatric Ulcerative Colitis

open access: yesFrontiers in Pediatrics, 2021
Background: Data on serum infliximab concentrations during induction in pediatric ulcerative colitis are limited. The study aim is to evaluate the relationship between serum infliximab concentrations during induction and short-term clinical remission in ...
Jennifer C. C. deBruyn   +10 more
doaj   +1 more source

Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis [PDF]

open access: yes, 2019
Background & Aims: Among immunosuppressive- and biologic-naïve patients with moderately-to-severely active Crohn's disease (CD), a higher proportion of those treated with the combination of infliximab and azathioprine achieved corticosteroid-free ...
D'Haens, Geert R.   +19 more
core   +1 more source

Home - About - Disclaimer - Privacy